Login / Signup

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.

Stephen J FreedlandUgo De GiorgiMartin GleaveBrad RosbrookQi ShenJennifer SuggGabriel P HaasNeal D Shore
Published in: BMJ open (2021)
NCT02319837.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • open label
  • clinical trial
  • squamous cell carcinoma
  • small cell lung cancer
  • study protocol
  • double blind
  • cell therapy